| Question |
Answer |
| ARDS | Acure respiratory distess syndrom- disorder characterized by respiratory insufficiency. May occur as a result from trauma, pneumonia, oxygen toxicity, gram-neg. sepsis, and systemic inflammatory response. |
| COPD | Airflow limitation that is not fully reversible, usually progressive, and associated w/an abnormal inflammatory response of the lung to noxious gases or particles. (Chronic Bronchitis,Emphysema,Asthma,and Bronchiectasis). |
| Code Name | Name assigned by manufacturer to an experimental chemical that shows potential as a drug. ex: SCH1000 |
| CF | Cystic Fibrosis: inherited disease of the exocrine glands, affecting the pancreas, respiratory system, and apocrine glands. Symptoms usually during infancy and are characterized by increased electrolytes in sweat, and chronic respiratory infection. |
| Generic Name | Name assigned to a chemical by the USNA council when the chemical appers to have therapeutic use and manufacturer wishes to market the drug. |
| Pharmacy | The preparation and dispensing of drugs |
| Pharmacognosy | The identification of sources of drugs, from plants and animals. |
| Pharmacogenetics | The study of the interrelationship of genetic differences and drug effects |
| Terapeutics | The art of treating disease with drugs |
| Toxicology | Study of toxic substances and their pharmacological actions, including antidotesw and poison control |
| Each drug has five different names, they are... | Chemical, code, official, generic, and Trade/Brand name |
| Pharmacodynamics | The machanisms of drug action by wich a drug molecule causes its effect in the body. |
| Pharmacokinetics | The time course and disposistion of a drug in the body, baseed on its absorption, distribution, metabolism, and elimination. |
| Pseudomonas aeruginosa | Gram-neg. orgnanism, primarily a nosocomial pathogen, causes UTI, URI, Dermatitis, soft tissue infections, bacteremia, bone and joint infections,etc.. Particularly in severely burned or immunosuppressed patients. |
| RSV | Respiratory syncytial virus: Virus that causes the formation of syncytial masses in cells, leads to imflammation of the bronchiles, which may cause respiratory distress in young infants. |
| Advantages of Aerosolized agents given by inhalation | Smaller doses for the same purpose and given systemically, fever and less sever side effects, onset of action is rapid, delivery targeed to respiratory system w/lower systemic bioavailability, painless, relatively safek, can be more convenient. |
| Antiinfective agents | Inhibition or eradication of specific infective agents, such as Pneumocytis carnii, RSV, CF or influenze A and B, antibiotics or antituberculous drugs. |
| Adrenergic Agernts | Relaxation of bronchial smooth muscle and bronchodilation, to reduce airway resistance and to improve ventilatory rates in airway obstruction in COPD'ers. |
| Anticholinergic Agents | Topical vasoconsstriction and decongestion, relaxation of cholinergically induced bronchocontriction to improve ventilatory flow rates in COPD |
| Mucoactive Agents | Modification nof the properties or Respiratory tract mucus, current agents lower viscosity and promote clearance of secreations |
| Corticosteroids | Reduction and control of airway inflammatory response, usually associated w/asthma or with seaonal or chronic rhinitis (URI). |
| Antiasthmatic Agents | Prevention of the onset and development of the asthmatic response, through inhibition of chemical mediators of inflammation |
| Exogenous Surfactants | Approved clinical use is by direct intratracheal instillation, for the purspose of restoring more normal lung compliance in RDS in newborns |
IVC Lesson 11
